

October 16, 2023



Stevanato Group Will Exhibit Vertiva™, Its On-Body Delivery System Platform for Injectable Therapies, Along with Full Primary Packaging and Devices Portfolio at PDA Universe and CPhI

[Stevanato Group S.p.A.](#) (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, is thrilled to announce its groundbreaking debut of the versatile on-body drug delivery platform Vertiva™ at the PDA Universe and the CPhI Barcelona in autumn.

Vertiva™ platform is the latest addition to Stevanato Group's comprehensive portfolio of products and devices for drug delivery. After the official announcement last summer, the live presentation of Vertiva™ at the PDA Universe (Gothenburg, Sweden, Oct. 17-18) and CPhI (Barcelona, Spain, Oct. 24-26) is a significant opportunity for Stevanato Group to showcase its commitment to advancing drug delivery technology in empowering pharmaceutical companies to bring innovative therapies to patients around the world.

At the PDA Universe of Pre-filled Syringes and Injection Devices Conference attendees visiting Stevanato Group's booth 69 will have the exclusive opportunity to witness firsthand the capabilities and potential of Vertiva™ platform for drug delivery and EZ-fill Smart™ ready-to-use vial platform for aseptic manufacturing.

During the conference, Stevanato Group's team will jointly share valuable insights with Bayer's and Thermo Fischer Scientific's experts to show how they are driving together transformative innovation to enhance contract manufacturing services and drug delivery devices portfolio to support biopharma companies.

Stevanato Group will be showcasing its complete portfolio of products, technologies, and innovations in Drug Containment Systems and Drug Delivery Devices - including Vertiva™ platform - at booth 2K20 during the CPhI show. Visitors will have the opportunity to meet the company's experts and sales representatives to learn about the advanced offer focused on biologics, including GLP-1 obesity drugs, vaccines, diabetes, and mRNA.

For more information about Stevanato Group and Vertiva™, please visit [Vertiva™ - Stevanato Group](#).

The complete programs of Stevanato Group's experts' speeches and tech talks scheduled for PDA Universe and CPhI are available at [Events - Stevanato Group](#).

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.

Contact

Media Stevanato Group

Stevanato Group: media@stevanatogroup.com

Investor Relations Stevanato Group

Lisa Miles: lisa.miles@stevanatogroup.com